Complete Regression of Cutaneous B-Cell Lymphoma in a Renal Transplant Patient After Conversion From Cyclosporin to Sirolimus

Mohsin, Nabil; Budruddin, M.; Kamble, Pramod; Khalil, M.; Pakkyarra, A.; Jha, Amitabh; Mohammed, Ehab; Ahmed, H.; Ahmed, Junaid; Thomas, Susan E.; Campistol, J M; Daar, Abdallah S.

doi:10.1016/j.transproceed.2007.03.092

Cited by 16 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to several independent studies on organ transplant patients who developed PTLD, substitution of the calcineurine inhibitor-based immunosuppressive therapy with an mTORC1 inhibitor resulted in a potent anti-PTLD effect leading to the full resolution of the PTLD lesions in some cases. [37][38][39][40][41][42][43] Perhaps even more strikingly, a similar therapeutic switch in transplant patients who developed the Kaposi sarcoma resulted in a sustained complete remission in all patients. [42][43][44][45] 822 El-Salem et al AJP August 2009, Vol.…”

Section: Discussionmentioning

confidence: 92%

“…2 The potential usage of mTORC1 inhibitors in AIDS patients may raise the concern of further increasing their immunodeficiency. However, transplant patients are also immunocompromised and yet mTORC1 inhibitors have proven efficacious in such patients, [37][38][39][40][41][42][43][44][45] as discussed above. This observation indicates that the direct effects of mTORC1 inhibitors on malignant cells by impairing their proliferation, survival, and angiogenesis, clearly outweigh immunosuppressive properties of the inhibitors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Activation of mTORC1 Signaling Pathway in AIDS-Related Lymphomas

El-Salem

Raghunath

Marzec

et al. 2009

The American Journal of Pathology

View full text Add to dashboard Cite

Using immunohistochemistry with antibodies against the phosphoserine residues in both S6rp and 4E binding protein 1, we identified the activation of the mammalian target of rapamycin (mTORC)1 pathway in 29 cases of AIDS-related lymphoma. These cases represented a diverse spectrum of histological types of nonHodgkin lymphoma (24 cases) and classic Hodgkin lymphoma (five cases). mTORC1 was also activated in the hyperplastic but not involuted follicles of HIV-associated lymphadenopathy in eight cases, supporting the notion that mTORC1 activation is a common feature of transformed lymphocytes irrespective of either their reactive or malignant phenotype. We also found that in B-cell lines that represent diffuse large B-cell lymphoma, Burkitt lymphoma, Epstein-Barr virus-infected lymphocytes, and human herpesvirus 8-positive primary effusion lymphoma, inhibitors of Syk, MEK, and, seemingly , phosphoinositide 3 kinases suppressed mTORC1 activation , in particular when these inhibitors were used in combination. These findings indicate that AIDS-related lymphoma and other histologically similar types of lymphomas that are derived from transformed B lymphocytes may display clinical responses to inhibitors that directly target mTORC1 or , possibly , upstream activators of the mTORC1 pathway.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Activation of mTORC1 Signaling Pathway in AIDS-Related Lymphomas

El-Salem

Raghunath

Marzec

et al. 2009

The American Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…Spontaneous remissions are primarily explained by an induction of cytokines and stimulation of antitumor immune response of the host (36)(37)(38). This hypothesis is supported by remission after infections (36,39,40), the remission of MALT lymphomas of the stomach after eradication of Helicobacter pylori (41,42), or remission after reduction of immune suppressive treatment (43)(44)(45)(46) or the start of treatment of HIV infection (47). Infiltration with T lymphocytes has been observed after remission (37,48,49).…”

Section: Discussionmentioning

confidence: 99%

Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under Viscum album Extracts After Resistance to R-CHOP: A Case Report

et al. 2018

View full text Add to dashboard Cite

show abstract

“…We have done a search for PTLD in the pathology file of Duke (Table 2). [8][9][10][11][12][13][14][15][16][17][18][19][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] Of these, about two-thirds of the cases occurred in male patients and one-third in female patients. The median age was 56 years with a range of 17-76 years, which seems to be significantly older than most reported age ranges for PTLD in general.…”

Section: Discussionmentioning

confidence: 99%

Primary Cutaneous Giant Cell Plasmacytoma in an Organ Transplant Recipient: A Rare Presentation of a Posttransplant Lymphoproliferative Disorder

Wang

Stoecker²

2010

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Posttransplant lymphoproliferative disorder (PTLD) is comprised of a spectrum of lymphoid diseases, ranging from early lesions, such as plasmacytic hyperplasia, to monomorphic neoplasms, including plasmacytoma-like lesions. Although PTLD may involve a variety of organs, primary cutaneous PTLD is rare. We report a unique case of Epstein-Barr virus (EBV)-positive primary cutaneous giant cell plasmacytoma developed 5 years after renal/pancreatic transplant in a 55-year-old male patient. The patient received local radiotherapy without reduction in immunosuppression and responded well. A review of the literature identified additional 49 cases of primary cutaneous B-cell PTLD, including 18 cases of plasmacytoma-like lesions. Primary cutaneous B-cell PTLD usually presents years after transplantation, has male preponderance, tends to occur on extremities, is frequently EBV-associated, and predicts a favorable clinical outcome. Unlike PTLD in general, in which EBV-positive cases usually occur earlier than EBV-negative ones, the longer presentation interval in the cutaneous PTLD seems to be uncorrelated to EBV status. Compared with other subtypes of cutaneous B-cell PTLD, plasmacytoma-like lesions have an increased male preponderance and tendency to present on the extremities. Although the majority of cases have been treated with reduction of immunosuppression, antiviral therapy and/or local radiotherapy, and a few with chemotherapy, the best therapeutic intervention for primary cutaneous B-cell PTLD remains to be further investigated with the analysis of more reported cases and large clinical trials.

show abstract

Complete Regression of Cutaneous B-Cell Lymphoma in a Renal Transplant Patient After Conversion From Cyclosporin to Sirolimus

Cited by 16 publications

References 44 publications

Activation of mTORC1 Signaling Pathway in AIDS-Related Lymphomas

Activation of mTORC1 Signaling Pathway in AIDS-Related Lymphomas

Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under Viscum album Extracts After Resistance to R-CHOP: A Case Report

Primary Cutaneous Giant Cell Plasmacytoma in an Organ Transplant Recipient: A Rare Presentation of a Posttransplant Lymphoproliferative Disorder

Contact Info

Product

Resources

About